Eiko Lifesciences Ltd - 540204 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Umesh Ravindranath More Eiko Lifesciences Ltd - 540204 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Rights Issue Update (Pre-Issue Advertisement) PNB Investment Services Limited (Lead Manager to the Issue) has submitted to BSE a copy of Pre-Issue Advertisement for rights issue of Eiko LifeSciences Limited (The Company) Eiko Lifesciences Ltd - 540204 - Announcement under Regulation 30 (LODR)-Newspaper Publication
We enclose herewith the copy of newspaper publication giving information of financial results as specified in Regulation 33 of Listing Regulations. The results are published in The Financial Express (English Newspaper) & Mumbai Lakshadweep (Marathi Newspaper) on July 12, 2023 Eiko Lifesciences Ltd - 540204 - Board Meeting Outcome for Board Meeting Outcome To Consider And Approve Unaudited Financial Results For Quarter Ending 30Th June 2023
The Board has considered and approved the Unaudited Financial Results for the Quarter ending 30th June 2023 Eiko Lifesciences Ltd - 540204 - Update On Rights Issue
PNB Investment Services Limited ("Lead Manager to the Issue") has submitted to BSE a copy of Abridged Letter of Offer ("ALOF"), Application Form and Rights Entitlement Letter for the Rights Issue of Eiko LifeSciences Limited. Eiko Lifesciences Ltd - 540204 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find enclosed herewith certificate under Regulation 74(5) of sebi (Depositories and Participants) Regulations 2018 for the quarter ended June 30, 2023 received from M/s Bigshare Services Pvt Ltd, Registrar and Share Transfer Agent of our Company. Request you to take the same on your record and oblige Eiko Lifesciences Ltd - 540204 - Update On Rights Issue
PNB Investment Services Limited ("Lead Manager to the Issue") has submitted to BSE a copy of Letter of Offer ("LOF") dated July 07, 2023 for the rights issue of Eiko LifeSciences Limited. Eiko Lifesciences Ltd - 540204 - Board Meeting Intimation for Board Meeting Intimation To Consider And Approve Unaudited Financial Results For The Quarter Ended 30Th June 2023
Eiko Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/07/2023 ,inter alia, to consider and approve unaudited financial results for the quarter ended June 30, 2023. This is for your information and records. Eiko Lifesciences Ltd - 540204 - Corporate Action-Intimation of Right issue
Subject: Intimation of Record date as per Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the purpose of the Rights Issue The Rights issue committee at its meeting held today, i.e., June 30, 2023 has fixed Friday, July 7, 2023 as the record date for the purpose of determining the equity shareholders who are entitled to receive the Rights Entitlement in the rights issue. Eiko Lifesciences Ltd - 540204 - Board Meeting Outcome for Outcome Of Rights Issue
Pursuant to regulation 30 and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that Right Issue Committee of the Board of Directors at their meeting held on Friday, 30th June 2023, have considered and approved the following terms of the Rights Issue: 1. Total number of Partly paid-up Rights Equity Shares and Rights Issue size: 55,44,178 Partly paid-up Rights Equity Shares of Rs.10/- each amounting to Rs. 2,494.88 Lakhs. 2. Right entitlement ratio: 2 (Two) Equity Share for every 3 (Three) Fully Paid Equity Shares held by the Existing Shareholders on the record. 3. Rights Issue Price: Rs.45/- per Rights Equity Share (including a premium of Rs.35/- per Rights Equity Share). Rs.13.50 per Rights Equity Share (including premium of Rs.10.50) to be paid on Application. Balance to be paid in not more than two calls as determined by our Board at its sole discretion. 4. Record date: Friday, July 07, 2023.